Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Merger with Cartesian Therapeutics","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Receives RMAT Designation for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"Cartesian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Cartesian Therapeutics

    Menu

    Cartesian Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cartesian Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing

              Details:

              The Company intends to use the net proceeds from the financing to fund its pipeline, which includes Descartes-08, a potential first-in-class mRNA CAR-T for patients with generalized myasthenia gravis.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Leerink Partners

              Deal Size: $130.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement July 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Doses First Patient in Phase 2 Trial of Descartes-08 for Lupus

              Details:

              Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for SLE.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Reports Positive Phase 2b Results for Descartes-08 in Myasthenia Gravis

              Details:

              Descartes-08, lead mRNA cell therapy candidate and a potential first-in-class mRNA CAR-T product candidate targeting B-cell maturation antigen (BCMA). It is under investigation for Myasthenia Gravis.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 02, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Receives RMAT Designation for Descartes-08 in Myasthenia Gravis

              Details:

              Descartes-08, the Company’s lead product candidate, is an autologous mRNA CAR-T directed against the B cell maturation antigen initially being developed for the treatment of MG.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 22, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

              Details:

              Descartes-08 is a potential first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). It is under phase 2 clinical development for the treatment of generalized myasthenia gravis.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 08, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Selecta Biosciences Announces Merger with Cartesian Therapeutics

              Details:

              The net proceeds will support the development of the Cartesian pipeline through the Phase 3 study of lead product candidate, Descartes-08, a potential first-in-class RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) for the treatment of myasthenia gravis.

              Lead Product(s): Descartes-08

              Therapeutic Area: Immunology Product Name: Descartes-08

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Recipient: Selecta Biosciences

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Merger November 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies

              Details:

              This $2 million competitive R&D award from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) will support Cartesian's clinical development for Descartes-30, the first RNA cell therapy for respiratory diseases.

              Lead Product(s): RNA Engineered Allogeneic Human Mesenchymal Stem Cells

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Descartes-30

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: $2.0 million Upfront Cash: Undisclosed

              Deal Type: Funding May 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer

              Details:

              Descartes-11 is engineered with Cartesian’s RNA Armory℠ platform to express its CAR molecules transiently instead of permanently, thereby reducing both short-term and long-term risks inherent with conventional CAR T-cell therapies.

              Lead Product(s): Descartes-11

              Therapeutic Area: Oncology Product Name: Descartes-11

              Highest Development Status: Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cartesian Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19

              Details:

              The Phase 1/2 clinical trial is the first-in-human study which aims to determine the safety and preliminary efficacy of Descartes-30 in patients with moderate to severe ARDS.

              Lead Product(s): Descartes 30

              Therapeutic Area: Infections and Infectious Diseases Product Name: Descartes 30

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY